Decursin
CAS No. 5928-25-6
Decursin( Decursin )
Catalog No. M18862 CAS No. 5928-25-6
Decursin is able to attenuate kainic acid-induced seizures and could have potential as an antiepileptic drug.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 72 | In Stock |
|
| 10MG | 110 | In Stock |
|
| 25MG | 245 | In Stock |
|
| 50MG | 438 | In Stock |
|
| 100MG | 626 | In Stock |
|
| 500MG | 1287 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDecursin
-
NoteResearch use only, not for human use.
-
Brief DescriptionDecursin is able to attenuate kainic acid-induced seizures and could have potential as an antiepileptic drug.
-
DescriptionDecursin is a phytochemical originally isolated from A. gigas with diverse biological activities. It reduces the growth of B16/F10 murine melanoma cells, via induction of apoptosis and increased caspase-3 activity.
-
In VitroCell Viability Assay Cell Line:DU145 cells Concentration:0, 25, 50, 100 μM Incubation Time:24, 28, 72, 96 h Result:Showed a dose- and time- dependent inhibition cell growth with 22% to 51%, 21%to 68%, 9% to 72%, 42% to 90% growth inhibition after 24, 48, 72, and 96 hours oftreatment, respectively. And caused 15%-45% cell death.Cell Cycle Analysis Cell Line:DU145 cells Concentration:0, 25, 50, 100 μM Incubation Time:12-96 h Result:Caused 52%, 65%, and 78% DU145 cells in G1phase.Western Blot Analysis Cell Line:DU145 cells Concentration:0, 25, 50, 100 μM Incubation Time:24, 48 h Result:Did not show any any alteration inprotein levels of CDK2, CDK4, CDK6, cyclin D1, and cyclin E, but dose-dependent decreased in the expression of these proteins except cyclin E at 48 h.
-
In VivoAnimal Model:C57BL/6J mice (LLC cells)Dosage:4 mg/kg Administration:S.c.; daily for 4 weeks Result:Delayed tumor formation and dramatically decreased tumor growth by inhibition of angiogenesis through VEGFR-2 signaling pathway.Animal Model:Eight-week-old adult C57BL/6J male and female miceDosage:50 mg/kg Administration:Intrathecal injection; three times at 2-day intervals, for 6 days Result:Demonstrated the analgesic ability in the in vivo model of paclitaxel-induced peripheral neuropathy.
-
SynonymsDecursin
-
PathwayOthers
-
TargetOther Targets
-
RecptorPKCα
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number5928-25-6
-
Formula Weight328.36
-
Molecular FormulaC19H20O5
-
Purity>98% (HPLC)
-
SolubilityDMSO : 125 mg/mL 380.68 mM;
-
SMILESCC(=CC(=O)OC1CC2=C(C=C3C(=C2)C=CC(=O)O3)OC1(C)C)C
-
Chemical Name3-methyl-2-butenoic acid, (7S)-7,8-dihydro-8,8-dimethyl-2-oxo-2H,6H-pyrano[3,2-g]-1-benzopyran-7-yl ester
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Mesna
Mesna(Uromitexan, Mesnex), a sulfhydryl compound that is used to reduce the incidence of hemorrhagic cystitis associated with certain chemotherapeutic agents.
-
SV40 T-Ag-derived NL...
This peptide, a nuclear localization signal DNA tagged to this peptide efficiently translocates into the cell nucleus.
-
Skp2 inhibitor 1
Skp2 inhibitor 1 is a Skp2-Cks1 interaction inhibitor (IC50: 2.8μM) with antitumor activity and can be used to study cancer.
Cart
sales@molnova.com